Skip to main content
Glama

NS Pros MCP Gateway

nj-mvc__resolve_entity

"What's the ticker for..." / "find the CIK for..." / "what's the LEI for..." / "what's the RxCUI for..." / "look up the ID for..." / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y", resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with p

Example tool call

This call uses example arguments supplied in the tool’s input schema.

{
  "id": 1,
  "jsonrpc": "2.0",
  "method": "tools/call",
  "params": {
    "arguments": {
      "type": "company",
      "value": "AAPL"
    },
    "name": "nj-mvc__resolve_entity"
  }
}

Input Schema

NameRequiredDescriptionDefault
typeYesEntity type: "company", "drug" or "lei" (a 20-character LEI; "company" also recognises an LEI by its check digits).
valueYesFor company: ticker (AAPL), CIK (0000320193 or 320193), LEI (HWUPKR0MPOU8FGXBT394), or name. A bare number is read as an SEC CIK only as 320193 or 0000320193; with a non-US `country`, or with 8-9 digits starting with 0 (a Companies House number), it is not a CIK and is not asserted as one. A bare number of 7 digits or fewer sent without `country` is always read as an SEC CIK, so a short register number (for example an Irish CRO or a US state filing number) that equals a real CIK will resolve to that SEC filer; send a non-US `country` with a foreign register number. A US state filing number cannot be resolved by number; search by company name instead. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY, for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.
countryNoOPTIONAL ISO 3166-1 alpha-2 of the country whose business register you mean ("NO", "FI", "JP", "GB", "FR", "EE", "BR"). Narrows the national-register fan-out and is often the difference between the right company and a US namesake, "Apple" with country "NO" is a Norwegian company, not Apple Inc. Omitting it searches every register we can name, which is the right default when you do not know. A bare number with a non-US country is that country's register number, never read as an SEC CIK (a 10-digit number still is). company only; ignored for drug.

Schema Changelog

Changes observed during successful MCP inspections.

  1. First observed

TDQS

B3.4/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

No annotations are supplied, so the description carries the full behavioral burden. It does disclose valuable behavior: cross-source resolution (SEC EDGAR CIK + GLEIF LEI), national-register fan-out, and the US-namesake hazard. But it never says what a result looks like (single match vs multiple candidates, ambiguity handling, not-found behavior), gives no auth/rate context, and the truncated tail leaves drug/lei behavior undisclosed.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness2/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Opens with a stray quote character, then runs one very long run-on sentence of slash-separated example phrasings before reaching the actual instruction. The 'SUPPORTED TYPES' block is truncated mid-word, so the text is both bloated up front and incomplete at the end.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness3/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Only 3 parameters, all fully described in the schema, and no output schema, so the bar is moderate. The routing and ambiguity guidance is genuinely useful, but the definition ends mid-sentence, leaving the behavior for the drug and lei entity types — a third of the enum — unexplained.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, so the schema already documents type, value and country in detail, and most of the description's parameter content duplicates it. The description adds little beyond the examples already in the schema, though it does reinforce the entity-name-only rule. Baseline 3 for a fully documented schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb+resource: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input', and enumerates the question shapes it answers (ticker, CIK, LEI, RxCUI, ownership). It is clearly a disambiguation/identity-resolution tool. However the 'SUPPORTED TYPES' section is cut off mid-word ('with p'), so the scope for drug and lei types is never fully stated.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Strong routing guidance: 'Use FIRST whenever you have a name but need an ID' plus a list of trigger phrasings. The country parameter gets explicit when-to-use/when-to-omit advice ('Omitting it searches every register we can name, which is the right default when you do not know'). It does not name any sibling as an alternative for the cases this tool is wrong for (e.g. entity_profile or compare_entities), so it stops short of a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.